Q!UW.yye1fxo
7 Feb 2018 - 7:06:12 PM
What if cures already exist?
What about the billions (public/private/govt) provided to fund cure dev?
Sheep.
These people are sick!
Q
Found this interdasting article in PubMed while waiting for the board to get sorted out, if anyone wants to check it out. Mebbe bookmark for future.
Mentions Chloroquine and HCQ…Never know, could save someone you love.
New drugs are not enough - drug repositioning in oncology: An update
International Journal of Oncology 2020 Mar; 56(3): 651–684.
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.
Research into repurposing drugs in oncology has been growing in the past years (9). One example is the Repurposing Drugs in Oncology project, an international collaboration initiated by several researchers, clinicians and patient advocates working in the non-profit sector (10). It is out of the sphere of this article to discuss the strategies for identifying repur-posing opportunities (knowledge mining, in silico approaches, high-throughput screening). For the analysis of those strategies, the review of Xue et al (11) is recommended. At present, >270 drugs are being analyzed for potential antitumor activity; of these, ~29% are on the World Health Organization Essential Medicines List (12). Furthermore, ~75% of these drugs are off-patent, and ~57% exhibited antitumor activity in human clinical trials (11). The purpose and significance of this review is to summarize updated information concerning the most promising drugs for repurposing in oncology, and combining analysis of their structures, the tumors that are affected by them, their diverse mechanisms of action and novel information regarding the clinical trials currently being conducted.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010222/